anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An adaptation of a pre-designed protocol will be used for the application of the Normocular Electrical Stimulation in the diaphragm. Current to be applied; Synchronous impulse at 30 Hz frequency, 1 sec beat increase time, 1 sec "on" (muscle contraction), 1 sec beat reduction time and 20 sec "off" (no warning) time. Two channels, each with two electrodes, will be placed in the seventh and eighth anterior intercostal space above and below the right and left sides of the xiphoid protrusion. The other two channels, each with two electrodes, will be placed on the right and left midaxillary line of the seventh and eighth anterior intercostal space. The application will be carried out for 6 weeks, 3 days a week, for 30 minutes daily.
The present invention provides methods for preparing liposomes, discotic lipids and other lipid nanoparticles using a multi-port manifold in which a stream of lipid solution containing an organic solvent is mixed with two or more streams of aqueous solution (e.g., buffer). In some aspects, the direction of at least some of the lipid solution flow and the aqueous solution flow are not directly opposite to each other. Thus, the process does not require dilution of the organic solvent as an additional step. In some embodiments, one of the solutions may further contain an Active Pharmaceutical Ingredient (API). The present invention provides a robust method of liposome processing with different lipid formulations and different payloads. The particle size, morphology and manufacturing scale can be controlled by varying the size and number of the manifold ports and by selecting the flow rates or flow rates of the lipid solution and the aqueous solution.
Individuals randomized to the self-monitoring control group will be asked to complete a weeklong sleep diary every other week for 8 weeks. The sleep diary will inquire about (1) the time of getting into bed; (2) the time at which the individual attempted to fall asleep; (3) sleep onset latency; (4) number of awakenings; (5) duration of awakenings; (6) time of final awakening; (7) final rise time; (8) perceived sleep quality (rated via Likert scale); and (9) an additional space for open-ended comments from the respondent. The control condition is designed to increase self-monitoring, which has been demonstrated to be an effective means of inducing change for various health behaviors such as diet and exercise.
The present invention provides an auxiliary health risk assessment method, which includes step S1, providing an inspection data, and the inspection data is at least one of a text type and a non-text type. Step S2 is to analyze the inspection data and classify the test data into the text type and the non-text type. Step S3 is to execute a natural language processing algorithm to obtain a first evaluation information from the inspection data. Step S4 is to execute an identification algorithm to obtain the second evaluation information from the inspection data. Step S5 is to execute a risk algorithm to calculate the first evaluation information and the second evaluation information to generate a corresponding health risk assessment from a risk factor map. Step S6 is to output the health risk assessment. The present invention also proposes an auxiliary health risk assessment system.
Monogenous preparations of conjugates of fibroblast growth factors (FGF) with cytotoxic agents are provided. Substantially all of the cytotoxic conjugates in the resulting monogenous preparation contain the same molar ratio of cytotoxic agent to polypeptide reactive with an FGF receptor. The conjugates are produced by chemical conjugation and also by expression of DNA encoding the conjugate to produce fusion proteins. The chemical conjugates are prepared by reacting FGF, which has at least one of the reactive cysteines replaced or deleted, with purified mono-derivatized saporin or with saporin that has been modified at or near one terminus by addition of a cysteine residue or replacement of a residue with cysteine. The resulting preparations are substantially monogenous. Fusion proteins are produced by expressing DNA constructs encoding muteins of an FGF in which one or more of any reactive cysteines have been deleted or replaced linked to DNA encoding a cytotoxic agent are also provided. The DNA constructs are expressed in host cells to produce monogenous preparations of cytotoxic FGF conjugates. In embodiments in which the FGF portion of the conjugate has been modified so that there are no cysteines available for reaction, the resulting compositions are free of aggregates. The monogenous preparations of conjugates provided herein are potent cytocidal agent to cells bearing the FGF receptor.
The present invention relates to a cancer cell target glycopeptides, and a contrast medium kit including the same. The glycopeptides is bound with an azide provided glycomonomer on a substrate peptide. The substrate peptide is specifically decomposed by a cathepsine B enzyme in a cancer cell, so an azide provided glycomonomer is expressed to the surface of a cell by glycoengineering. Thus, a contrast medium can be applied by targeting the same. Accordingly, expression is limited in a normal cell, but expression is specifically performed in a cancer cell. In particular, expression is specifically performed in transition cancer. Azide is exposed to the surface of a cell only by a cathepsine B enzyme which is rarely secreted to the outside of a cell, so a cancer cell can be selectively contrasted by an azide-specific contrast medium.
AIMS: To validate the sensitivity and specificity of the Zenicor One handheld ECG device for detection of atrial fibrillation in an outpatient clinical setting.
METHODS AND RESULTS: Patients attending outpatient clinics at Danderyd Hospital (n = 220) were examined with one lead handheld ECG immediately after standard care 12‑lead ECG recording. Twelve recordings were excluded (atrial flutter or pacing) or missing. The recordings were dichotomously categorized as "atrial fibrillation" or "not atrial fibrillation" by two senior cardiologists. In cases of diverging interpretations, a third senior cardiologist had the deciding vote. Sensitivity and specificity in diagnosing atrial fibrillation was calculated with 12‑lead ECG as gold standard. Sensitivity and specificity for diagnosis of atrial fibrillation with one lead handheld ECG and 12‑lead ECG as gold standard was 98% and 99% respectively.
CONCLUSION: In a health-care outpatient setting, Zenicor One handheld ECG had high sensitivity and specificity for detection of atrial fibrillation when compared with 12‑lead ECG.
Vitamin E TPGS/drug compositions and methods are provided which obviate the need for surfactants or non-evaporated co-solvents because the active drug component is dissolved directly into Vitamin E TPGS to form a true molecular solution-not an emulsion or a micro-emulsion. The invention provides a slowly dissolving TPGS/Drug matrix that absorbs gastrointestinal fluid into the matrix at the dosage form/fluid interface, where a gel-like liquid crystal is formed. This gel front forms a liquid crystal boundary where drug dissolution is highest. At this liquid crystal/GI fluid boundary, a synchronization takes place in which the rate of formation of liquid crystals equals the dissolution rate of liquid crystals at the water interface, thereby giving controlled order release of the drug into the GI tract. The rate of dissolution is also controlled by the geometry of the dosage form. The solid Vitamin E TPGS/drug matrices of the invention can be solidified and compressed into tablets or filled into capsules, with other excipients, binders and/or fillers. The solid TPGS/drug solution of the invention also can be made into an immediate release liquid formulation upon addition of water, or into a controlled release system solid tablet by the use of impermeable or semi-permeable barriers or coatings surrounding portions of the tablet.
The present invention relates to aesthetic cosmetology and physiotherapy, particularly, to the method of deep cleansing of skin using grapes and wine's steam. It's also useful for skin anti-aging, getting rid of overweight and cellulite, removing harmful substances.The skin is pre-cleansed with wine steam, then peeling is done. Peeling is carried out in steps. In the first step, chemical peeling is performed at a temperature of 50-85° ° C. for 30-45 minutes in the steam cabin by steaming the patient's body with a steam mixture that consists of wine steam containing active substances which is obtained by getting in contact with medical herbs.In the second step, mechanical peeling is carried out with a special puree, which contains the following components, wt. %. alcohol-free hot wine—10-30, ground dry grape seed—2.5-10, freshly ground grape—10-30, grape seed oil—1-5 and hot water up to 1 kg.
Participants randomized to the control group will receive a single dietetic counseling session (weeks 1-2) on the 2020-2025 Dietary Guidelines for Americans (DGA) which is considered a healthy diet pattern for prediabetes. Diet adherence will be assessed with a 7-day food diary in the first week and then a 3-day food diary in weeks 2-12. Study personnel and/or the study RDN will follow up with the participants during the study to review the food diaries.
This arm (n = 4) of healthy male volunteers won't receive an LPS challenge or any of the study treatments. This group will be used to familiarise the study team with the study procedures and to establish the effect of placement of an intrathecal catheter on systemic and neuroinflammation.
The point stimulated will be the Trachea, which is one millimeter in the direction of the auditory meatus. This point does not cause risk to the research participant. As sessions will held twice a week for a total of 10 sessions.
NEW MATERIAL:A compound shown by the formula I (R<1> is H, or alkyl; R<2> is H, hydroxyl-protecting group; R<3> is hydroxymethyl, protected hydroxymethyl, formyl, 3-oxo-trans-1-octenyl, etc.) and its derivative. EXAMPLE:9(0)-Methano-5-cyano-PGI USE:An antitumor agent having extremely weak inhibitory action on blood platelet aggregation. PREPARATION:A conjugated diene-cyanide shown by the formula II is subjected to stereospecific 1,4 reduction reaction in the presence of a catalyst of a metallic carbonyl compound or its complex, to give a compound shown by the formula I. The protecting group of the compound is selectively removed, the resultant compound is then oxidized to give an aldehyde, the aldehyde is reacted with a compound shown by the formula IV (R<5> is H, or methyl), to give an alpha,beta-unsaturated ketone. Then, this compound is reduced, the hydroxyl group is deprotected and the ester is hydrolyzed, to give a compound shown by the formula V.
Corticosteroid injections and high energy ESWT are standard therapies for lateral epicondylitis at Walter Reed National Military Medical Center. While corticosteroid injections have been shown to be moderately effective in the short term for the condition, a significant minority of patients remains symptomatic. Low energy ESWT has mixed results in the orthopaedic literature, but to date no study has specifically examined the effects of high energy ESWT. The investigators plan to randomize a total of 80 patients with the diagnosis of lateral epicondylitis to either corticosteroid injection or high energy ESWT, and follow them for a total of 12 months. Primary outcomes will be Disabilities of the Arm, Shoulder, and Hand (DASH) score, Patient Reported Tennis Elbow Evaluation (PRTEE) score, Mayo Elbow Score, Veterans Rand-36, and return-to-work status. Patients will be surveyed at baseline, 6 weeks, 3 months, and 6 months. All assessments will be done by an independent physician examiner who is blinded to the treatment received.
PURPOSE: A pressure of approximately 15-25 mmHg is used for effective compression therapy to prevent and treat hypertrophic scar formation in patients with burns. However, conventional facial compression garments present challenges owing to inadequate pressure distribution in curved areas such as the cheeks, around the mouth, and the slope of the nose. This study aimed to evaluate the utility of a custom-made 3D compression mask equipped with pressure sensors to treat facial burn scars.
METHODS: This single-blinded, prospective randomized controlled trial was conducted between May and October 2023, involving 48 burn scars in 12 inpatients with facial burns. We created the custom-made 3D compression mask equipped with pressure sensors, inner lined with biocompatible silicon, and a harness system using 3D printing technology, which can continuously monitor whether an appropriate pressure of 15-25 mmHg maintains. The biological scar properties, Vancouver Scar Scale (VSS), and Patient and Observer Scar Assessment Scale (POSAS) scores in patients with facial burns were assessed before applying the compression mask and garment and at 4 and 12 weeks after application.
RESULTS: Pre-application assessment of biological scar properties, VSS, and POSAS revealed no statistically significant differences between the 3D mask and control groups (p > 0.05 for all). Throughout the 12-week application, skin hydration and scar thickness significantly increased (p < 0.001) and reduced (p = 0.010), respectively, in the 3D mask group compared to the control group. Additionally, significant improvements in scar pliability (p = 0.004) and height (p = 0.009) of VSS, itching (p = 0.047), scar stiffness (p = 0.001), thickness (p = 0.011), and irregularity (p < 0.001) of POSAS-patient component, and scar thickness (p = 0.001), pliability (p = 0.012), and surface area (p = 0.027) of the POSAS-observer component were observed in 3D mask group throughout the 12-week application compared to the control group.
CONCLUSION: The customized 3D compression mask equipped with pressure sensors significantly improved scar thickness, skin hydration, and various assessment scale parameters throughout the 12-week application.
The incidence of hyperuricemia (HUA) is on the rise, posing a significant threat to human health. Several probiotics have shown potential in treating HUA; however, the critical role of intestinal metabolites in this therapy remains inadequately understood. Our study demonstrated that Lacticaseibacillus rhamnosus 2016SWU.05.0601 not only reduced the expression levels of xanthine dehydrogenase and the content and activity of xanthine oxidase in the liver but also regulated the uric acid transporters expression in the kidney, thereby attenuating HUA in mice. Additionally, L. rhamnosus 2016SWU.05.0601 modulated the gut microbiota and metabolite abundance in HUA mice. Correlation analysis revealed that the gut microbiota metabolite taurohyocholate played a vital role in the treatment of HUA by L. rhamnosus 2016SWU.05.0601, as confirmed in HUA cell models. Our research provides a significant theoretical basis for elucidating the mechanisms by which probiotics alleviate HUA and for developing functional ingredients for HUA treatment.
The invention relates to a method for treating a solid tumor in somatic tissue, or treating or preventing metastasis of such a tumor, in a patient comprising administering to the patient an amount of one or more antigens specific to the somatic tissue effective to induce an immune response against the somatic tissue. In distinction to the above-described immunotherapies, the antigen or antigens administered to the patient are not specific to the tumor, but are specific to the somatic tissue from which the tumor originated. Tissue specific antigens (TSAs) are expected to be more immunogenic than TSTAs and are more numerous. As such, the therapy of the invention has the advantage of initiating and sustaining a strong immune response against the somatic tissue and tumor until the tumor has been rejected. The therapy also has the advantage of eliciting an immune response against metastatic cancer. In another embodiment, the invention relates to vaccines comprising the tissue specific antigen in a pharmaceutically acceptable carrier and in a size and manner to elicit a class I MHC immune response. In another embodiment, the invention relates to a method for the identification and isolation of a tissue specific antigen which can elicit or induce a class I MHS response.
Tuberculosis (TB) alone caused over a billion deaths in the last 200 years, making it one of the deadliest diseases to humankind. Understanding the immune mechanisms underlying protection or pathology in TB is key to uncover the much needed innovative approaches to tackle TB. The scavenger receptor cysteine-rich molecule CD5 antigen-like (CD5L) has been associated with TB, but whether and how CD5L shapes the immune response during the course of disease remains poorly understood. Here, we show an upregulation of CD5L in circulation and at the site of infection in C57BL/6 Mycobacterium tuberculosis-infected mice. To investigate the role of CD5L in TB, we studied the progression of M. tuberculosis aerosol infection in a recently described genetically engineered mouse model lacking CD5L. Despite the increase of CD5L during infection of wild-type mice, absence of CD5L did not impact bacterial burden, histopathology or survival of infected mice. Absence of CD5L associated with a modest increase in the numbers of CD4+ T cells and the expression of IFN-γ in the lungs of infected mice, with no major effect in overall immune cell dynamics. Collectively, this study confirms CD5L as a potential diagnostic biomarker to TB, showing no discernible impact on the outcome of the infection.
1413186 Encapsulating medicaments TOYO JOZO CO Ltd 19 June 1973 29112/73 Heading B8C [Also in Division A5] Water-insoluble and slightly water-soluble medicaments are encapsulated by dispersing or dissolving them in a solution of a film-forming material in an organic solvent (or mixture thereof) which is immiscible in water (or miscible up to no more than 10%), has a boiling point not above 100 C. and a dielectric constant not more than 10, dispersing the solution or dispersion thus obtained in a vehicle comprising an aqueous solution of a hydrophilic colloid or surface active agent and causing the organic solvent to evaporate, e.g. by heating. Suitable film-forming materials are cellulose derivatives and synthetic polymers, e.g. polyvinyl acetate, polyvinyl formal, polystyrene, polycarbonates, polyesters, polybutadiene and various copolymers. Numerous medicaments are mentioned including antibiotics, steroids and various other substances, e.g. phenacetin, diazepam, hexobarbital, strychnine nitrate.
The invention aims at providing a helicobacter pylori resistant recombined VacA specificity yolk antibody with convenient available material, simplicity, economical efficiency and high stability. Sucralfate with volume percent of between 30 and 50 percent is added to the antibody to serve as a protectant, thereby improving the stability of the specificity yolk antibody against acid and pepsin, strengthening the anti-freeze thawing capacity, and maintaining the activity of the yolk antibody at room temperature. In addition, the self protective function of the sucralfate on the gastric mucosa can also be brought into play, and the sucralfate can also be used for other specificity yolk antibodies. Regarding the preparation, the material of the antibody is conveniently available, simple and economical. Two kinds of liquids can be simply mixed according to the proportion for direct taking. The specificity yolk antibody can be used for treating helicobacter pylori infection.
Introduction: Dysfunctions of the lower urinary tract are non-motor symptoms common engines in Parkinson's disease (PD). Urodynamic changes in PD include overactive bladder (OB), characterized by urgency with or without urge incontinence , usually with frequency and nocturia . The aim of this study is to evaluate the efficacy and effectiveness of the treatment of OB in patients with PD with the use of a specific treatment: Posterior Tibial Nerve Electrostimulation (PTNE). Materials and methods: This is test-clinical, double-blind, randomized, controlled comparison with placebo. The research will be conducted with patients diagnosed with PD and symptoms of OB in the Clinical Hospital of Porto Alegre, in the Movement Disorders and Urogynecology Ambulatories. The patients are divided into two groups, one of which receives placebo stimulation (often below the therapeutic threshold). They will be assessed before and after 12 weeks of treatment with home PTNE through specific form of questionnaires assessing incontinence, quality of life and voiding diary. After the end of treatment will be made up of patients to verify the effectiveness of treatment in 30 to 90 days. Hypothesis: Through this research the investigators hope to determine the true efficacy of this treatment method with PTNE in OB in PD with a high level of evidence, seeking to improve urinary symptoms and quality of life in this patient population.
Elderly in this group will receive multimodal exercise program. The duration of exercise is 60 minutes and frequency is 2 times/week.
Before the procedure, the researcher informed the parents of the newborns in the musical and lighted baby crib mobile group about the study procedure and purpose. The mobile was fixed 60 cm above the newborn's eye level to prevent contamination and trauma. After obtaining written consent, the researcher collected data using the 'Newborn Information Form' through face-to-face interviews. Once the form was completed, the mobile was activated. One minute later, the nurse performed the blood draw. Parents and nurses observed the infant's behavior during and immediately after the procedure to assess pain and stress. They were then asked to mark the maximum pain and stress experienced by the baby on the ALPS-Neo pain and stress rating scale.
Non-randomized study with interrupted time series and open-label, in which women were enrolled and advised to not consumed foods containing prebiotic, probiotic and fibers, and citrus fruits and beverages during 30 days before of intervention (n=10; BMI 23.8 kg/m2; 28 years). After 30 days, the participants will consume during 60 days 300 mL of orange juice daily. After 60 days of orange juice intervention, the participants will be submitted to 30 days of washout. Samples of blood, urine and feces will collect in five different occasions (baseline, 30 day, 60 day, 90 day, and 120 day) in order to evaluate the prebiotic effect of orange juice on gut microbiota and in the bioavailability of its flavanones. The recruitment process began in September 2016 and the intervention was carried out from October 2016 to February 2017, and the data analysis will start in February 2017. The sample number took into account variances on blood hesperitin levels with a type I error α = 0.05 and a type II error β = 0.2 (80% power) (Silveira et al., 2015). The minimum sample size should have six individuals into the same group. Considering an approximately 15% dropout rate, the final sample size of study was constituted by 10 women. Primary endpoint is the changes in total bacteria population (Lactobacillus spp., Bifidobacterium spp., and reduction of Clostridium spp.) that can result in increased of butyric, acetic, and propionic acid concentrations, and reduction of ammonium production. Secondary endpoint is enhancement of bioavailability of flavanones (hesperitin, naringenin) and metabolites in the blood, urine and feces. Kolmogorov Smirnov and Levene test will be used to assess the normality and homogeneity of data, respectively. One-way analysis of variance (ANOVA) will be apply to determine the intervention effect over the time 0, 30 day, 60 day, 90 day, and 120 day). P significance was set up ≤ 0.05.